Next Article in Journal
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy
Next Article in Special Issue
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Previous Article in Journal
Melanoma Cancer Stem Cells: Markers and Functions
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(3), 35; doi:10.3390/cancers8030035

Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy

Institute of Cancer Therapeutics, University of Bradford, Bradford, West Yorkshire BD7 1DP, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Jonas Cicenas
Received: 30 January 2016 / Revised: 3 March 2016 / Accepted: 8 March 2016 / Published: 14 March 2016
(This article belongs to the Special Issue Small GTPases in Cancer)
View Full-Text   |   Download PDF [1663 KB, uploaded 14 March 2016]   |  

Abstract

Tumour suppressor proteins, such as p53, BRCA1, and ABC, play key roles in preventing the development of a malignant phenotype, but those that function as transcriptional regulators need to enter the nucleus in order to function. The export of proteins between the nucleus and cytoplasm is complex. It occurs through nuclear pores and exported proteins need a nuclear export signal (NES) to bind to nuclear exportin proteins, including CRM1 (Chromosomal Region Maintenance protein 1), and the energy for this process is provided by the RanGTP/RanGDP gradient. Due to the loss of DNA repair and cell cycle checkpoints, drug resistance is a major problem in cancer treatment, and often an initially successful treatment will fail due to the development of resistance. An important mechanism underlying resistance is nuclear export, and a number of strategies that can prevent nuclear export may reverse resistance. Examples include inhibitors of CRM1, antibodies to the nuclear export signal, and alteration of nuclear pore structure. Each of these are considered in this review. View Full-Text
Keywords: Nuclear export; CRM1; Ran; nucleocytoplasmic transport Nuclear export; CRM1; Ran; nucleocytoplasmic transport
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

El-Tanani, M.; Dakir, E.-H.; Raynor, B.; Morgan, R. Mechanisms of Nuclear Export in Cancer and Resistance to Chemotherapy. Cancers 2016, 8, 35.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top